Answers are grounded in this paper and cite their sources.
The human respiratory syncytial virus (HHRSV) has a remarkable importance as a causative agent of respiratory tract infection in children. Preterm infants or those affected by some chronic conditions are especially compromised by HHRSV infection. Monoclonal antibodies against HRSV F protein have been used to prevent severe disease. This study evaluates a group of 58 newborns (median age 10 months) in use of Palivizumab prophylaxis presenting any symptom of respiratory tract infection by tests currently available. Positive nasopharyngeal samples were then analyzed and viral load compared to a control group of non-risk outpatient's children without prophylaxis.
No takes yet. Share an insight, caveat, or question.
Moreira et al. (2017) studied this question.
Synapse has enriched 6 related papers. Consider them for comparative context: